Recent ventures in this regard include the development of anti‐CD3/anti‐CLEC12A bispecific antibodies.7, 8, 9 The upcoming roles of CLEC12A as a cancer stem cell marker and potential treatment target emphasize the need of knowing the details of its expression pattern on early stem and progenitor cells in healthy individuals. Here, CLEC12A is linked to cancer.